Modified anti-tenascin antibodies and methods of use
AssigneeHoffmann-La Roche Inc.
InventorsRalf HOSSE, Ekkehard MOESSNER, Pablo UMANA
Life of this patent
Estimating the term…
Abstract
The present invention relates to improved antibodies specific for Tenascin-C (TnC), in particular domain specific anti-TnC antibodies with improved cross-species reactivity. In addition, the invention relates to polynuleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies and methods of using them in the treatment of disease.
Claims24
An antibody that specifically binds to Tenascin-C (TnC), wherein said antibody comprises:
- (i) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:
- 49, a heavy chain CDR2 of SEQ ID NO:
- 50 and a heavy chain CDR3 of SEQ ID NO:51;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 37, a light chain CDR2 of SEQ ID NO:
- 38 and a light chain CDR3 of SEQ ID NO:
- 39;
- or
- (ii) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:
- 52, a heavy chain CDR2 of SEQ ID NO:
- 53 and a heavy chain CDR3 of SEQ ID NO:
- 54;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 40, a light chain CDR2 of SEQ ID NO:41 and a light chain CDR3 of SEQ ID NO:
- 42;
- wherein said antibody has cross-species reactivity.
The antibody of laim 1, wherein said antibody has an improved affinity.
A pharmaceutical formulation comprising an antibody that specifically binds to Tenascin-C (TnC), wherein said antibody comprises:
- (i) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:
- 49, a heavy chain CDR2 of SEQ ID NO:
- 50 and a heavy chain CDR3 of SEQ ID NO:51;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 37, a light chain CDR2 of SEQ ID NO:
- 38 and a light chain CDR3 of SEQ ID NO:
- 39;
- or
- (ii) a heavy chain variable region combrising a heavy chain CDR1 of SEQ ID NO:
- 52, a heavy chain CDR2 of SEQ ID NO:
- 53 and a heavy chain CDR3 of SEQ ID NO:
- 54;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 40, a light chain CDR2 of SEQ ID NO:41 and a light chain CDR3 of SEQ ID NO:
- 42;
- wherein said antibody has cross-species reactivity.
A method of treating an individual having a disease characterized by expression of TnC, the method comprising administering to a patient in need thereof an antibody that specifically binds to Tenascin-C (TnC), wherein said antibody comprises:
- (i) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:
- 49, a heavy chain CDR2 of SEQ ID NO:
- 50 and a heavy chain CDR3 of SEQ ID NO:51;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 37, a light chain CDR2 of SEQ ID NO:
- 38 and a light chain CDR3 of SEQ ID NO:
- 39;
- or
- (ii) a heavy chain variable region combrising a heavy chain CDR1 of SEQ ID NO:
- 52, a heavy chain CDR2 of SEQ ID NO:
- 53 and a heavy chain CDR3 of SEQ ID NO:
- 54;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 40, a light chain CDR2 of SEQ ID NO:41 and a light chain CDR3 of SEQ ID NO:
- 42;
- wherein said antibody has cross-species reactivity.
The method of manufacturing an antibody that specifically binds to Tenascin-C (TnC) for treating cancer, wherein said antibody comprises:
- (i) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO:
- 49, a heavy chain CDR2 of SEQ ID NO:
- 50 and a heavy chain CDR3 of SEQ ID NO:51;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 37, a light chain CDR2 of SEQ ID NO:
- 38 and a light chain CDR3 of SEQ ID NO:
- 39;
- or (ii) a heavy chain variable region combrising a heavy chain CDR1 of SEQ ID NO:
- 52, a heavy chain CDR2 of SEQ ID NO:
- 53 and a heavy chain CDR3 of SEQ ID NO:
- 54;
- and a light chain variable region comprising a light chain CDR1 of SEQ ID NO:
- 40, a light chain CDR2 of SEQ ID NO:41 and a light chain CDR3 of SEQ ID NO:
- 42;
- wherein said antibody has cross-species reactivity.
Dependencies are inferred from the claim text.